In summary, the decreased incretin effect in patients with T2D is attributed mainly to an impaired insulinotropic action of GIP, potentially because of impaired β-cell function and down-regulation, degradation or alternative splicing of the GIP receptor under conditions of hyperglycemia. This evidence concerns the gene GCG and Hyperglycemia.